This issue opens with the 2026 European Drug Report from the Commission and the EU Drugs Agency, which points to a drug situation that is more available, more potent and increasingly tied to organised crime. We then turn to the Health Council (EPSCO) of 16 June, where ministers advanced the European Biotech Act, the reform of medical-device rules and the question of pharmaceutical resilience — a reminder of how strategic health policy has become for Europe.
From Italy, our member FNOPI takes up the Eurispes Report, which places nurses at the centre of the country’s healthcare turnaround.
And from Rome, we report on the 8th ESNO Congress, where the ENC brought its experience to the table to interrogate where European regulation is driving real change, and where the gap between Brussels and the bedside remains stubbornly wide.